Survival with Optune + TMZ vs TMZ alone was significantly higher at the 2-year landmark analysis and remained higher at 5 years1
Median OS was significantly extended with Optune—by nearly 5 months (P<0.001)1
Optune + TMZ also significantly improved PFS vs TMZ alone1
- Median PFS: 6.7 months vs 4.0 months (P<0.001)
More time on Optune predicted increased significant survival benefit3
*Based on the amount of time Optune was turned on and providing therapy over the
course of a month. This data reflects the average patient usage of Optune for the first 6 months of treatment (months 1-6).4
† Approximation, based on monthly usage.
‡ vs TMZ alone.
- Monthly usage was a predictor of survival benefit, independent of other prognostic factors such as KPS, age, or MGMT methylation status3
of patients received a survivalbenefit from Optune because they used it more than half the time (n=388/450)3
Long-term use is supported by strong evidence
The updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers now include alternating electric field therapy (Optune) in combination with temozolomide (TMZ) following maximal safe resection and standard brain radiation therapy with concurrent TMZ as Category 1 recommended treatment option for patients with newly diagnosed supratentorial glioblastoma (GBM) and good performance status.* There is uniform NCCN consensus for this recommendation based on high-level evidence (Category 1).
MGMT, O-6-methylguanine—DNA methyltransferase; OS, overall survival; PFS, progression-free survival.
* The NCCN defines good performance as Karnofsky Performance Score (KPS) ≥60. The trial for which the IFU is based used an eligibility criteria of KPS ≥70.
The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
References: 1. Optune Instructions for Use. Novocure 2018. 2. Stupp R, Idbaih A, Steinberg DM, et al. Prospective, multi-center phase III trial of tumor treating fields together with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. Presented at: 2017 Annual Meeting of the American Association for Cancer Research; April 1-5, 2017; Washington, DC. Oral presentation LBA AACR CT007. 3. Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial [published online ahead of print December 1, 2018]. J Neurooncol. https://doi.org/10.1007/s11060-018-03057-z. 4. Novocure Data on File OPT-135. 5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers. V.1.2018. © 2018 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed March 20, 2018. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.